Windlas Biotech has debuted at Rs 439.00 on the BSE, down by 21 points or 4.57% from its issue price of Rs 460.
The scrip is currently trading at Rs 416.55, down by 43.45 points or 9.45% from its issue price. It has touched a high and low of Rs 452.10 and Rs 407.25 respectively. So far 2.33 lakh shares were traded on the counter.
The offering, which was open for subscription between August 04, 2021 and August 06, 2021, was subscribed 22.46 times. The issue price was fixed at Rs 460 per share i.e. at upper end of price band of Rs 448-460 apiece.
Windlas Biotech is into domestic pharmaceutical formulations contract development and manufacturing business.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: